(Q46711852)

English

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis

scientific article published on 4 February 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

meglumine antimoniate

1 reference

based on heuristic

inferred from title

Ricardo T. Fujiwara

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

12

object named as

Steven Reed

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

author name string

Jorge Miret

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Evaldo Nascimento

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Weverton Sampaio

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

João Carlos França

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

André Vale

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Edelberto Santos Dias

7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Edvá Vieira

8

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Roberto Teodoro da Costa

9

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Wilson Mayrink

10

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Antonio Campos Neto

11

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

language of work or name

0 references

publication date

4 February 2008

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

26

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

1585-1594

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

12

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

Canine leishmaniasis. A review based on 95 cases in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Atypical forms of canine leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Distribution and relationships between clinical and biopathological parameters in canine leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Veterinary Group of Lupino

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Immunotherapy for drug-refractory mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Infectivity of seropositive dogs, showing different clinical forms of leishmaniasis, to Lutzomyia longipalpis phlebotomine sand flies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Use of Ranks in One-Criterion Variance Analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Visceral leishmaniasis: new health tools are needed

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

T-cell and cytokine responses in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of enzyme-linked immunosorbent assay using crude Leishmania and recombinant antigens as a diagnostic marker for canine visceral leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Kala-azar in the Rio Doce, Minas Gerais area. Results of prophylactic measures]

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of zoonotic visceral leishmaniasis: is it time to change strategies?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for Treating Leishmaniasis with Sodium Stibogluconate (Pentostam) and Review of Pertinent Clinical Studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18328956

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2008.01.026

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18328956

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46711852&oldid=2127722312"